An interventional study of ADUNU program for delivery of RHD care services in Rheumatic Heart Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in Uganda. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati — 7 open to participants now, 7 under way, 2 of them phase 3. Rheumatic Heart Disease · Children's Hospital Medical Center, Cincinnati.
Among the 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 with no phase, and was the 6th registered.
62 studies on the registry are indexed under Rheumatic Heart Disease; 26 are open to participants now.
Browse Rheumatic Heart Disease studies →7 of the 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati are open now, in 2 countries. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 5–20
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 5–8 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 5–8
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
By country, each count listing its studies:
Of the 11 Rheumatic Heart Disease studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 5 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 221 is close to the median of 221 across 37 interventional studies indexed under Rheumatic Heart Disease.
Median enrollment 629 across the 10 interventional studies, 1,423 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
1 of the studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05783375Children's Hospital Medical Center, CincinnatiAccelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective study is to evaluate the feasibility, sustainability, and public health impact of a district-based program for secondary prevention of Rheumatic Heart Disease (RHD) in Uganda.
ADUNU is a non-randomized experiment, testing a strategy for implementing an evidence-based practice, decentralized RHD preventive services.
The objectives of the study are to:
Objective 1: Demonstrate the impact of ADUNU, using the RE-AIM framework to assess program Reach, Effectiveness, Adoption, Implementation and Maintenance.
Objective 2: Estimate the cost-effectiveness and budget impact of ADUNU.
ADUNU is a public health initiative that will be deployed the Uganda ministry of health in partnership with the District Health Offices (DHO) in two districts. The program will be overseen by the Technical and Quality Assurance (TAQA). ADUNU's main components will include a RHD testing program which consists of community and facility based echocardiographic screening of children and young adults and a registry based secondary prophylaxis injections of Benzathine penicillin G (BPG) at local health centers III and IVs in both districts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals and healthcare providers residing and working in the involved Ugandan Districts.
Other: ADUNU program for delivery of RHD care services
The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.
Proportion of persons with RHD reached by the ADUNU program
This objective will involve only secondary analysis of de-identified data collected by districts using routine MOH data collection procedures supplemented by some routine program data during the Ministry's rollout of the ADUNU Programme Package. The number of individuals screened and screening positivity rates will be extracted from screening logs implemented and maintained by DHOs and assessed by modality (school fairs, health days, passive health center screening, and active outreach to family members of RHD diagnosed).
Time frame: 5 year endpoint
Proportion of persons with RHD enrolled in care, retained and adherent to treatment
Secondary analysis of data from the districts RHD registry will be used to assess the proportion of registrants enrolled, retained and adherent to secondary prophylaxis.
Time frame: 3 months
Proportion of persons with RHD enrolled in care, retained and adherent to treatment
Secondary analysis of data from the districts RHD registry will be used to assess the proportion of registrants enrolled, retained and adherent to secondary prophylaxis.
Time frame: 24 months
Adoption and implementation of the ADUNU program at the organization level surveys
Brief surveys will be filled out by providers who are acting as administrators of their health centre and will include questions on a range of logistic (e.g., availability of commodities and stockouts, basic infrastructure reliability) and organizational readiness topics (e.g., staffing levels and turnover, organization of patient scheduling, district support visits)
Time frame: Baseline
Adoption and implementation of the ADUNU program at the organization level surveys
Brief surveys will be filled out by providers who are acting as administrators of their health centre and will include questions on a range of logistic (e.g., availability of commodities and stockouts, basic infrastructure reliability) and organizational readiness topics (e.g., staffing levels and turnover, organization of patient scheduling, district support visits)
Time frame: 24 months
Adoption and implementation of the ADUNU program at the provider level
Two types of data collection activities from frontline providers will be used to understand individual provider-level adoption and maintenance over time: provider surveys and in-depth interviews of providers. A standardized survey instrument on Adoption and a standardized checklist on implementation fidelity that will be completed by the research staff via direct observation. Research staff will use a standardized checklist that will be developed from the core elements of RHD testing (e.g., ultrasound technique, saving of images) and secondary prevention (e.g., injection technique, adequate post-injection monitoring for anaphylaxis)
Time frame: 6 months
Adoption and implementation of the ADUNU program at the patient level interview
We will conduct a limited number of interviews of registry patients in each district stratified by adherence outcomes as well as age group (adult vs children).
Time frame: 24 months
Cost-analysis of the ADUNU program
To estimate program costs, we will use the standardized data collection instruments. Our instruments will measure fixed and capital costs, as well as variable or recurrent costs. Ingredients-based costing will be used for drugs and consumables, personnel costs, and equipment costs, whereas gross costing will be used for "indirect" costs such as facility rents and utilities and maintenance. Relevant data for ingredients-based costing include study data on participant healthcare utilization and price lists of drugs, consumables, and equipment. DHO budget sheets for health facilities and overall health service utilization will be used for gross costing. Both financial costs and economic costs will be measured. We will also estimate of out-of-pocket costs borne by registrants, which will allow us to estimate costs from the patient/household perspective.
Time frame: 3 year endpoint
Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →